Persistence of SARS-CoV-2-antibodies against N, S and RBD after natural infection
Background and Objectives: Coronavirus disease 2019 (COVID-19) pandemic has affected most countries in the world. Monitoring the humoral immune responses during the natural course of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection and the duration of them provide useful information for the development of vaccination strategies against this virus and its emerging variants. The importance of the antibody response especially neutralizing antibodies in long-term immunity to SARS-CoV-2 is significant.
Materials and Methods: The present study is a cross-sectional study of sero-epidemiological type that has been proposed to compare the persistence of Immunoglobulin G (IgG) against N (nucleocapsid), S (spike) and RBD (receptor-binding domain) proteins in the community after the time of primary disease. A total of 652 serum samples were collected from hospital staff working in COVID wards, as well as a number of community members with different occupations, among those with positive antibody titers, 86 participated in the resampling test before vaccination.
Results: There was no association between antibody titer and disease severity (p>0.05). A significant decrease in Ab levels was observed in the paired second samples. The highest rate of decrease was related to anti-N, then anti-RBD and anti-S IgG levels, respectively. There is a significant relationship between the initial antibody titer and its reduction over time (p-value <0.05).
Conclusion: Our data revealed that humoral immunity following natural infection of SARS-CoV-2 is detectable for at least 4 months, regardless of disease severity. The most decrease in antibody titer over time was related to anti-N IgG levels.
2. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020; 26: 845-848.
3. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JC, Wang Z, Cho A, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020; 584: 437-442.
4. Hanson KE, Caliendo AM, Arias CA, Englund JA, Lee MJ, Loeb M, et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19. Clin Infect Dis 2020: ciaa760.
5. Favresse J, Eucher C, Elsen M, Gillot C, Van Eeckhoudt S, Dogné J-M, et al. Persistence of anti-SARS-CoV-2 antibodies depends on the analytical kit: a report for up to 10 months after infection. Microorganisms 2021; 9: 556.
6. Batra M, Tian R, Zhang C, Clarence E, Sacher CS, Miranda JN, et al. Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes. Sci Rep 2021; 11: 3455.
7. Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andréll J, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection. Med 2021; 2: 281-295. e4.
8. Feng C, Shi J, Fan Q, Wang Y, Huang H, Chen F, et al. Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery. Nat Commun 2021; 12: 4984.
9. Tan Y-J, Goh P-Y, Fielding BC, Shen S, Chou C-F, Fu J-L, et al. Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. Clin Diagn Lab Immunol 2004; 11: 362-371.
10. Wu H-S, Hsieh Y-C, Su I-J, Lin T-H, Chiu S-C, Hsu Y-F, et al. Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients. J Biomed Sci 2004; 11: 117-126.
11. Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res 2014; 194: 175-183.
12. Özçürümez MK, Ambrosch A, Frey O, Haselmann V, Holdenrieder S, Kiehntopf M, et al. SARS-CoV-2 antibody testing-questions to be asked. J Allergy Clin Immunol 2020; 146: 35-43.
13. Perez-Saez J, Zaballa M-E, Yerly S, Andrey DO, Meyer B, Eckerle I, et al. Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clin Microbiol Infect 2021; 27: 1695.e7-1695.e12.
14. Kwok KO, Lai F, Wei WI, Wong SYS, Tang JW. Herd immunity-estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect 2020; 80(6): e32-e33.
15. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020; 323: 1406-1407.
16. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci 2020; 63: 706-711.
17. Zeng F, Wu M, Wang J, Li J, Hu G, Wang L. Over 1‐year duration and age difference of SARS‐CoV‐2 antibodies in convalescent COVID‐19 patients. J Med Virol 2021; 93: 6506-6511.
18. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020; 383: 1724-1734.
19. Alzaabi AH, Ahmed LA, Rabooy AE, Zaabi AA, Alkaabi M, AlMahmoud F, et al. Longitudinal changes in IgG levels among COVID-19 recovered patients: A prospective cohort study. PLoS One 2021; 16(6): e0251159.
20. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity. Immunity 2020; 53: 925-933. e4.
21. Kutsuna S, Asai Y, Matsunaga A. Loss of anti-SARS-CoV-2 antibodies in mild COVID-19. N Engl J Med 2020; 383: 1695-1696.
22. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 2020; 383: 1085-1087.
23. Wang Y, Li J, Li H, Lei P, Shen G, Yang C. Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients. Int Immunopharmacol 2021; 90: 107271.
24. Yousefi Z, Taheri N, Dargahi M, Chaman R, Binesh E, Emamian MH, et al. Long-term persistence of anti-SARS-COV-2 IgG antibodies. Curr Microbiol 2022; 79: 96.
25. Thangaraj JWV, Kumar MS, Kumar CG, Kumar VS, Kumar NP, Bhatnagar T, et al. Persistence of humoral immune response to SARS-CoV-2 up to 7 months post-infection: cross-sectional study, South India, 2020–21. J Infect 2021; 83: 381-412.
26. Miyakawa K, Kubo S, Stanleyraj Jeremiah S, Go H, Yamaoka Y, Ohtake N, et al. editors. Persistence of robust humoral immune response in Coronavirus disease 2019 convalescent individuals over 12 months after infection. Open Forum Infect Dis 2021; 9: ofab626.
27. Trinité B, Tarrés-Freixas F, Rodon J, Pradenas E, Urrea V, Marfil S, et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Sci Rep 2021; 11: 2608.
28. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJ, Simmons R, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet 2021; 397: 1459-1469.
|Issue||Vol 15 No 6 (2023)|
|SARS-CoV-2; Antibody persistence; COVID-19; Humoral immunity; Long-term immunity|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|